Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22964351 | 1.00 | SLC6A4 (0.50) | SLC6A4SLC6A2AKR1C2AKR1C1SLC6A3 | |
| SCHEMBL11397144 | 0.80 | SLC6A2 (0.51) | SLC6A4SLC6A2SLC6A3AHRALDH1A1 | |
| SCHEMBL22726430 | 0.79 | SLC6A4 (0.47) | SLC6A4SLC6A2AKR1C2SLC6A3AHR | |
| SCHEMBL11390760 | 0.78 | SLC6A2 (0.50) | SLC6A4SLC6A2SLC6A3AHRALDH1A1 | |
| SCHEMBL6203511 | 0.77 | SLC6A2 (0.49) | SLC6A4SLC6A2SLC6A3AHRALDH1A1 | |
| SCHEMBL6203514 | 0.77 | SLC6A2 (0.49) | SLC6A4SLC6A2SLC6A3AHRALDH1A1 | |
| SCHEMBL254524 | 0.77 | AHR (0.50) | SLC6A4SLC6A2SLC6A3AHRALDH1A1 | |
| SCHEMBL16870352 | 0.76 | SLC6A4 (0.39) | SLC6A4SLC6A2SLC6A3AHRALDH1A1 | |
| SCHEMBL16649763 | 0.76 | SLC6A2 (0.45) | SLC6A4SLC6A2AKR1C2SLC6A3AHR | |
| SCHEMBL16649917 | 0.76 | SLC6A2 (0.45) | SLC6A4SLC6A2AKR1C2SLC6A3AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961231-B2 | NTCP inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-03-30 | — | — | US | disclosed |
| US-20210040072-A1 | NTCP Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040072-A1 | NTCP Inhibitors | HAVCR2, NPC1, HMGCR | SLC6A4 713/4885SLC6A2 928/4885AKR1C2 1507/4885 |
| US-10961231-B2 | NTCP inhibitors | HAVCR2, NPC1, HMGCR | SLC6A4 713/4885SLC6A2 928/4885AKR1C2 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.